{"groups":[{"description":"Experimental: GVHD prophylaxis\n\nSubjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine .\n\nMatched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus.","id":"FG000","title":"Experimental: GVHD Prophylaxis"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"54"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"54"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 55 subjects were consented, but one subject was not enrolled due to disease progression or death prior to protocol therapy.","recruitmentDetails":"Patients with advanced, refractory, or high-risk hematologic cancers who were deemed suitable for myeloablative conditioning were recruited from one institution."}